http://www.esac-mare.net/2008/12/08/default-risk-premium-drp/ Productivity at your daily life ! Sat, 04 Feb 2012 03:10:57 -0600 http://wordpress.org/?v=2.8.6 hourly 1 http://www.esac-mare.net/2008/12/08/default-risk-premium-drp/comment-page-1/#comment-3026 Zombie Fud » Blog Archive » COX-II Inhibitors and the Future Wed, 01 Apr 2009 04:10:08 +0000 http://localhost/wp1/?p=97#comment-3026 [...] If anti-inflammatory agents can prevent or slow down the progression of Alzheimer’s disease, then could they also work against milder forms of memory loss? Merck, the pharmaceutical company that manufactures rofecoxib (Vioxx), one of the new Cyclo-oxygenase (COX)-II inhibitors that has been approved by the FDA to treat arthritis, has started a large-scale placebocontrolled clinical trial to evaluate the new medication’s effects in treating people with mild cognitive impairment. Similarly, Searle, which makes another COX-II inhibitor called celecoxib (Celebrex), is completing a similar trial in people with mild cognitive impairment. [...] [...] If anti-inflammatory agents can prevent or slow down the progression of Alzheimer’s disease, then could they also work against milder forms of memory loss? Merck, the pharmaceutical company that manufactures rofecoxib (Vioxx), one of the new Cyclo-oxygenase (COX)-II inhibitors that has been approved by the FDA to treat arthritis, has started a large-scale placebocontrolled clinical trial to evaluate the new medication’s effects in treating people with mild cognitive impairment. Similarly, Searle, which makes another COX-II inhibitor called celecoxib (Celebrex), is completing a similar trial in people with mild cognitive impairment. [...]

]]>